¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"receptor organ"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • vestigial organ
    ÈçÀû±â°ü
  • visual organ
    ½Ã°¢±â°ü
  • vomeronasal organ
    º¸½ÀÄÚ±â°ü, ¼­°ñºñ±â°ü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
  • cold receptor
    ³Ã°¢¼ö¿ë±â
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • corpuscular receptor
    ¼Òü¼ö¿ëü
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • distance receptor
    ¿ø°Ý¼ö¿ë±â
  • dominant receptor
    ¿ì¼º¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • vestigial organ
    ÈçÀû±â°ü
  • visual organ
    ½Ã°¢±â°ü
  • vomeronasal organ
    º¸½ÀÄÚ±â°ü, ºñ¼­°ñ±â°ü
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • receptor autoradiography
    ¼ö¿ëüÀÚ°¡¹æ»ç¼±¼ú
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • cold receptor
    ³Ã°¢¼ö¿ëü
  • complement receptor
    µµ¿òü¼ö¿ëü, º¸Ã¼¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • receptor assay
    ¼ö¿ëÃ¼ÃøÁ¤
  • receptor autoradiography
    ¼ö¿ëü ÀÚ±â¹æ»ç¼±ÃÔ¿µ¼ú
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blockade
    ¼ö¿ëüÂ÷´Ü
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
  • receptor cell
    ¼ö¿ëü ¼¼Æ÷
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò(¡­÷òÎÕý£áÈ).
  • receptor gradient
    ¼ö¿ëü°æ»ç.
  • receptor hypothesis
    ¼ö¿ëü°¡¼³
  • receptor imaging
    ¼ö¿ëü¿µ»ó(È­)
  • receptor potential
    ¼ö¿ë±âÀüÀ§.
  • receptor sensitivity
    ¼ö¿ëü °¨¼ö¼º
  • receptor site
    ¼ö¿ëüºÎÀ§.
  • receptor stimulants
    ¼ö¿ëüÀÚ±ØÁ¦.
  • receptor supersensitivity
    ¼ö¿ëü Ãʰ¨¼ö¼º(áôéÄô÷ õ±Êïáôàõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • maltose channel (lamda receptor)
    ¸»Å佺Åë·Î (¶÷´Ù¼ö¿ëü)
  • mmuscle receptor
    ±Ù°¨¼ö±â
  • mu receptor
    ¹Â¼ö¿ëü
  • muscarinic receptor
    ¹«½ºÄ«¸° ¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±Ù¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾ ¼ö¿ëü
  • olfactory receptor
    Èİ¢°¨¼ö±â
  • olfactory receptor cells
    Èİ¢¼ö¿ë¼¼Æ÷
  • opiate receptor
    ¾ÆÆí¼ö¿ëü(áôé»ô÷)
  • opiate receptor
    ¾ÆÆí¼ö¿ëü.
  • opioid receptor
    ¾ÆÆí¾ç¼ö¿ëü
  • opioid receptor
    ¾ÆÆí°è¹°Áú¼ö¿ëü.
  • opioid receptor
    ¾ÆÆí¾ç¹°Áú¼ö¿ëü.
  • opioid receptor
    ¾ÆÆí¾ç¹°Áú¼ö¿ëü.
  • paciniform receptor
    ÆÄÄ¡´Ï¾ç °¨¼ö±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
OSF organ system failure; osteoclast-stimulating factor; outer spiral fiber; overgrowth stimulating fact...
OTD oculotrichodysplasia; oral temperature device; organ tolerance dose
SCO sclerocystic ovary; somatic crossing-over; subcommissural organ
SOSF single organ system failure
SSO sequence-specific oligonucleotide [probe]; Society of Surgical Oncology; special sense organ
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
SFO Subfornical Organ
TOD Target organ damage
UNOS United Network for Organ Sharing
UNOS United Network of Organ Sharing
VNO vomeronasal organ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mechanical organ
    Àΰø Àå±â
  • olfactory organ
    ÈÄ ±â°ü
  • organ blood barrier
    Àå±â-Ç÷¾×°£ °ü¹®
  • organ death
    Àå±â »ç¸Á
  • organ gain access
    ±âÁú À̵æ Á¢±Ù
  • organ of respiration
    È£Èí±â
  • organ of speech
    ¾ð¾î ±â°ü
  • organ of vision
    ½Ã°¢±â
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
  • organ transplantation
    Àå±â À̽Ä
  • pelvic organ
    °ñ¹Ý³»Àå±â
    °ñ¹Ý°­¿¡ ³õ¿©ÀÖ´Â Àå±â.
  • reproductive organ
    »ý½Ä ±â°ü
  • rupture of organ
    ³»Àå ÆÄ¿­
  • secretory organ
    ºÐºñ ±â°ü
  • sense organ
    °¨°¢±â, °¨°¢ ±â°ü
    ¿ÜºÎ ȯ°æÀÇ º¯È­¸¦ ÀÚ±ØÀ¸·Î ÀνÄÇÏ´Â ±â´ÉÀ» Çϰí ÀÖ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
cAMP receptor protein catabolite (gene) activator protein
GABA receptor <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B.
A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor.
See: amino acid receptor superfamily.
B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines.
(05 Jan 1998)
p60 tumour necrosis factor receptor-associated kinase <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor
Registry number: EC 2.7.10.-
Synonym: p60 tnf receptor-associated kinase, p60-trak
(26 Jun 1999)
gamma aminobutyric acid receptor <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B.
A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor.
See: amino acid receptor superfamily.
B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines.
(05 Jan 1998)
GAP-1 receptor tyrosine kinase <enzyme> Similar to rasGTPase-activating proteins; inhibits signaling activity of let-60; amino acid sequence given in first source
Registry number: EC 2.7.1.-
Synonym: gap-1 gene product, gap-1 protein
(26 Jun 1999)
gene rearrangement, alpha-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, beta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, delta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, gamma-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
(12 Dec 1998)
genes, T-cell receptor DNA sequences, in cells of the t-lymphocyte lineage, that code for T-cell receptors. The tcr genes are formed by somatic rearrangement (see gene rearrangement, t-lymphocyte and its children) of germline gene segments, and resemble ig genes in their mechanisms of diversity generation and expression.
(12 Dec 1998)
genes, T-cell receptor alpha DNA sequences encoding the alpha chain of the T-cell receptor. The genomic organization of the tcr alpha genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor beta DNA sequences encoding the beta chain of the T-cell receptor. The genomic organization of the tcr beta genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor delta DNA sequences encoding the delta chain of the T-cell receptor. The delta-chain locus is located entirely within the alpha-chain locus.
(12 Dec 1998)
genes, T-cell receptor gamma DNA sequences encoding the gamma chain of the T-cell receptor. The human gamma-chain locus is organised similarly to the tcr beta-chain locus.
(12 Dec 1998)
receptor 1. A molecular structure within a cell or on the surface characterised by selective binding of a specific substance and a specific physiologic effect that accompanies the binding, for example, cell surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments and immunoglobulins and cytoplasmic receptors for steroid hormones.
2. A sensory nerve terminal that responds to stimuli of various kinds.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á